Digoxin therapy: A persisting interest despite contrary winds

Archives of Cardiovascular Diseases

Volumn 103, Issue 5, 2010, Pages 281-284

  Juillière, Yves ^a   Selton Suty, Christine ^a  

^a Heart Failure and Valvular Heart Diseases Unit   (France)

Author keywords

Blockers of the renin angiotensin system; Digoxin; Health cost; Heart failure; Morbimortality

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; SPIRONOLACTONE; VALSARTAN; CARDIOTONIC AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEART FAILURE; HUMAN; MORBIDITY; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; MORTALITY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; COST-BENEFIT ANALYSIS; DIGOXIN; DRUG COSTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77956648741     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2010.04.001     Document Type: Article

References (24)

1. G.S. Francis Pathophysiology of chronic heart failure Am J Med 110 Suppl. 7A 2001 37S 46S
2. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
3. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556-64.
4. S.B. Arnold, R.C. Byrd, and W. Meister Long-term digitalis therapy improves left ventricular function in heart failure N Engl J Med 303 1980 1443 1448
5. S.H. Rahimtoola Digitalis therapy for patients in clinical heart failure Circulation 109 2004 2942 2946
6. B.F. Uretsky, J.B. Young, and F.E. Shahidi Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial PROVED Investigative Group J Am Coll Cardiol 22 1993 955 962
7. M. Packer, M. Gheorghiade, and J.B. Young Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors RADIANCE Study N Engl J Med 329 1993 1 7 (Pubitemid 23182871)
8. S.S. Rathore, Y. Wang, and H.M. Krumholz Sex-based differences in the effect of digoxin for the treatment of heart failure N Engl J Med 347 2002 1403 1411
9. K.F. Adams Jr., M. Gheorghiade, and B.F. Uretsky Clinical benefits of low serum digoxin concentrations in heart failure J Am Coll Cardiol 39 2002 946 953
10. A. Ahmed, M.W. Rich, and T.E. Love Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial Eur Heart J 27 2006 178 186
11. S.S. Rathore, J.P. Curtis, and Y. Wang Association of serum digoxin concentration and outcomes in patients with heart failure JAMA 289 2003 871 878 (Pubitemid 37430346)
12. K.F. Adams Jr., J.H. Patterson, and W.A. Gattis Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis J Am Coll Cardiol 46 2005 497 504
13. A.S. Dhaliwal, A. Bredikis, and G. Habib Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy Am J Cardiol 102 2008 1356 1360
14. V.V. Georgiopoulou, A.P. Kalogeropoulos, and G. Giamouzis Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy Circ Heart Fail 2 2009 90 97
15. J.G. Cleland, and D. Cullington Digoxin: quo vadis? Circ Heart Fail 2 2009 81 85
16. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
17. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
18. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
19. C. Adamopoulos, A. Ahmed, and R. Fay Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial Eur J Heart Fail 11 2009 1099 1105
20. J.J. McMurray, J. Ostergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
21. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
22. J.M. Brophy Rehabilitating digoxin Eur Heart J 27 2006 127 129
23. R.E. Ward, M. Gheorghiade, and J.B. Young Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure J Am Coll Cardiol 26 1995 93 101
24. M. Gheorghiade, and E. Braunwald Reconsidering the role for digoxin in the management of acute heart failure syndromes JAMA 302 2009 2146 2147